Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology
Background and AimNon-alcoholic fatty liver disease (NAFLD) is closely related to cardiovascular diseases (CVD). A newly proposed definition is metabolic dysfunction-associated fatty liver disease (MAFLD), which was changed from NAFLD. The clinical effect of this change on abnormalities of cardiac s...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.935390/full |
| _version_ | 1828185891561013248 |
|---|---|
| author | Dandan Peng Zhenqiu Yu Mingwei Wang Junping Shi Lei Sun Yuanyuan Zhang Wenbin Zhao Chen Chen Jiake Tang Chunyi Wang Jie Ni Wen Wen Jingjie Jiang |
| author_facet | Dandan Peng Zhenqiu Yu Mingwei Wang Junping Shi Lei Sun Yuanyuan Zhang Wenbin Zhao Chen Chen Jiake Tang Chunyi Wang Jie Ni Wen Wen Jingjie Jiang |
| author_sort | Dandan Peng |
| collection | DOAJ |
| description | Background and AimNon-alcoholic fatty liver disease (NAFLD) is closely related to cardiovascular diseases (CVD). A newly proposed definition is metabolic dysfunction-associated fatty liver disease (MAFLD), which was changed from NAFLD. The clinical effect of this change on abnormalities of cardiac structure and function is yet unknown. We aimed to examine whether MAFLD is associated with left ventricular (LV) diastolic dysfunction (LVDD) and cardiac remolding and further identify the impact of different subgroups and severity of MAFLD.MethodWe evaluated 228 participants without known CVDs. Participants were categorized by the presence of MAFLD and the normal group. Then, patients with MAFLD were subclassified into three subgroups: MAFLD patients with diabetes (diabetes subgroup), overweight/obesity patients (overweight/obesity subgroup), and lean/normal-weight patients who had two metabolic risk abnormalities (lean metabolic dysfunction subgroup). Furthermore, the severity of hepatic steatosis was assessed by transient elastography (FibroScan®) with a controlled attenuation parameter (CAP), and patients with MAFLD were divided into normal, mild, moderate, and severe hepatic steatosis groups based on CAP value. Cardiac structure and function were examined by echocardiography.ResultsLVDD was significantly more prevalent in the MAFLD group (24.6% vs. 60.8%, p < 0.001) compared to the normal group. The overweight subgroup and diabetes subgroup were significantly associated with signs of cardiac remolding, including interventricular septum thickness, LV posterior wall thickness, left atrial diameter (all p < 0.05), relative wall thickness, and LV mass index (all p < 0.05). Additionally, moderate-to-to severe steatosis patients had higher risks for LVDD and cardiac remolding (all p-values < 0.05).ConclusionMAFLD was associated with LVDD and cardiac remolding, especially in patients with diabetes, overweight patients, and moderate-to-to severe steatosis patients. This study provides theoretical support for the precise prevention of cardiovascular dysfunction in patients with MAFLD. |
| first_indexed | 2024-04-12T07:10:44Z |
| format | Article |
| id | doaj.art-9648de0a97344cec9a00c1fe11957ab7 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-12T07:10:44Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-9648de0a97344cec9a00c1fe11957ab72022-12-22T03:42:39ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-07-011310.3389/fendo.2022.935390935390Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac MorphologyDandan Peng0Zhenqiu Yu1Mingwei Wang2Junping Shi3Lei Sun4Yuanyuan Zhang5Wenbin Zhao6Chen Chen7Jiake Tang8Chunyi Wang9Jie Ni10Wen Wen11Jingjie Jiang12School of Clinical Medicine, Guizhou Medical University, Guiyang, ChinaThe Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaDepartment of Hepatology, The Affiliated Hospital and Institute of Hepatology and Metabolic Disease, Hangzhou Normal University, Hangzhou, ChinaDepartment of Hepatology, The Affiliated Hospital and Institute of Hepatology and Metabolic Disease, Hangzhou Normal University, Hangzhou, ChinaDepartment of Cardiovascular Ultrasonic Center, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaBackground and AimNon-alcoholic fatty liver disease (NAFLD) is closely related to cardiovascular diseases (CVD). A newly proposed definition is metabolic dysfunction-associated fatty liver disease (MAFLD), which was changed from NAFLD. The clinical effect of this change on abnormalities of cardiac structure and function is yet unknown. We aimed to examine whether MAFLD is associated with left ventricular (LV) diastolic dysfunction (LVDD) and cardiac remolding and further identify the impact of different subgroups and severity of MAFLD.MethodWe evaluated 228 participants without known CVDs. Participants were categorized by the presence of MAFLD and the normal group. Then, patients with MAFLD were subclassified into three subgroups: MAFLD patients with diabetes (diabetes subgroup), overweight/obesity patients (overweight/obesity subgroup), and lean/normal-weight patients who had two metabolic risk abnormalities (lean metabolic dysfunction subgroup). Furthermore, the severity of hepatic steatosis was assessed by transient elastography (FibroScan®) with a controlled attenuation parameter (CAP), and patients with MAFLD were divided into normal, mild, moderate, and severe hepatic steatosis groups based on CAP value. Cardiac structure and function were examined by echocardiography.ResultsLVDD was significantly more prevalent in the MAFLD group (24.6% vs. 60.8%, p < 0.001) compared to the normal group. The overweight subgroup and diabetes subgroup were significantly associated with signs of cardiac remolding, including interventricular septum thickness, LV posterior wall thickness, left atrial diameter (all p < 0.05), relative wall thickness, and LV mass index (all p < 0.05). Additionally, moderate-to-to severe steatosis patients had higher risks for LVDD and cardiac remolding (all p-values < 0.05).ConclusionMAFLD was associated with LVDD and cardiac remolding, especially in patients with diabetes, overweight patients, and moderate-to-to severe steatosis patients. This study provides theoretical support for the precise prevention of cardiovascular dysfunction in patients with MAFLD.https://www.frontiersin.org/articles/10.3389/fendo.2022.935390/fullmetabolic dysfunction-associated fatty liver diseasecardiac remodelingleft ventricular diastolic dysfunctiontype 2 diabetes mellitusobesity |
| spellingShingle | Dandan Peng Zhenqiu Yu Mingwei Wang Junping Shi Lei Sun Yuanyuan Zhang Wenbin Zhao Chen Chen Jiake Tang Chunyi Wang Jie Ni Wen Wen Jingjie Jiang Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology Frontiers in Endocrinology metabolic dysfunction-associated fatty liver disease cardiac remodeling left ventricular diastolic dysfunction type 2 diabetes mellitus obesity |
| title | Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology |
| title_full | Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology |
| title_fullStr | Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology |
| title_full_unstemmed | Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology |
| title_short | Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology |
| title_sort | association of metabolic dysfunction associated fatty liver disease with left ventricular diastolic function and cardiac morphology |
| topic | metabolic dysfunction-associated fatty liver disease cardiac remodeling left ventricular diastolic dysfunction type 2 diabetes mellitus obesity |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.935390/full |
| work_keys_str_mv | AT dandanpeng associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT zhenqiuyu associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT mingweiwang associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT junpingshi associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT leisun associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT yuanyuanzhang associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT wenbinzhao associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT chenchen associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT jiaketang associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT chunyiwang associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT jieni associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT wenwen associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology AT jingjiejiang associationofmetabolicdysfunctionassociatedfattyliverdiseasewithleftventriculardiastolicfunctionandcardiacmorphology |